We retrospectively examined the cases of renal tumors experienced between 1993 and 2002 to evaluate the rates of incidence and preoperative identification by imaging techniques, mainly CT, of retroperitoneal venous abnormalities. Among a total of 178 renal cell carcinomas and 13 renal benign tumors, the incidence of multiplicity of renal veins was 5.3%, restricted to operatively confirmed cases (9 out of 170 cases). None of these multiplicities could be detected by preoperative radiological examinations. Other major venous abnormalities included duplications of inferior vena cava and retroaortic left renal vein and spontaneous splenorenal shunt which were all correctly diagnosed preoperatively. The incidence of these abnormalities was 0.52% (1 out of 191 cases for each). A retroperitoneal venous anomaly is common, but urologists must have sufficient knowledge about acquired retroperitoneal venous abnormalities, which seem rather uncommon, to be prepared for the potential hazards which may occur during urological operations.

Keywords:
Acquired venous abnormalities, Congenital venous anomalies, Retroperitoneal surgery
This content is only available via PDF.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.